PubMed Health⌕ Search

PubMed · 6285071

Ferrokinetics after high-dose methotrexate therapy.

Abstract

After high-dose methotrexate with doses ranging from 2-10 g/m2, ferrokinetics were performed in 11 patients with different tumors. Iron-III-citrate-59Fe was injected at methotrexate serum concentrations ranging between 2.7 x 10(-7) -1.3 x 10(-8) M. With MTX levels greater than or equal to 4.2 x 10(-8) M the plasma iron clearance was always retarded, and the plasma iron turnover was diminished in 5 of 6 patients with levels of 3.1-8.9 x 10(-8) M at the time of the injection. In all cases with MTX concentrations greater than or equal to 5 x 10(-8) M the 59Fe-utilization as the measure of effective erythropoiesis was reduced pathologically below normal range. These results show that the erythropoiesis resumes its normal extent even in case of normal methotrexate clearance only when the methotrexate serum concentrations have fallen down below 5 x 10(-8) and that erythropoiesis is more sensitive against methotrexate toxicity than the granulocytopoiesis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Schalhorn, H Sauer, W Wilmanns, G Stupp-Poutot. 1981-10-01. Ferrokinetics after high-dose methotrexate therapy.. https://doi.org/10.1007/bf01746198

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.

The topoisomerase I inhibitor, topotecan, is approved for the treatment of recurrent small-cell lung cancer (SCLC) and ovarian cancer (OC). Patients with recurrent SCLC and OC typically experience multiple relapses and receive multiple rounds of chemotherapy. In these settings, disease stabilisation is considered a treatment benefit, and quality-of-life effects and cumulative toxicities of treatments should be considered. Many patients with recurrent cancer may be predisposed to treatment-related adverse events because of advanced age, renal impairment or extensive prior therapy. The standard regimen of topotecan, 1.5 mg/m(2) on days 1-5 of a 21-day cycle, has generally mild nonhaematological toxicity and a well-defined haematological toxicity profile characterised by reversible and noncumulative neutropenia. Alternative regimens may lower the incidence of haematological toxicities and maintain antitumour efficacy. Topotecan may provide physicians with a versatile therapeutic option for the treatment of patients with relapsed SCLC or OC.

Carcinoma, Small Cell↗